Reported Earnings • May 16
Third quarter 2026 earnings released: EPS: JP¥39.37 (vs JP¥16.59 in 3Q 2025) Third quarter 2026 results: EPS: JP¥39.37 (up from JP¥16.59 in 3Q 2025). Revenue: JP¥1.52b (up 18% from 3Q 2025). Net income: JP¥297.0m (up 140% from 3Q 2025). Profit margin: 20% (up from 9.6% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to JP¥1,803, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 190% over the past year. Reported Earnings • Feb 14
Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025) Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan. Tillkännagivande • Dec 27
WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026 WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥1,667, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 121% over the past year. Reported Earnings • Nov 16
First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025) First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to JP¥1,594, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 88% over the past year. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to JP¥1,331, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 53% over the past year. New Risk • Oct 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks High level of debt (60% net debt to equity). Market cap is less than US$100m (JP¥8.11b market cap, or US$53.8m). Tillkännagivande • Sep 27
WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025 WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025 Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥1,097, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 1.0% over the past year. Tillkännagivande • Aug 15
WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025 WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025. Tillkännagivande • Jun 24
WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025 WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025 New Risk • Jun 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (89% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (JP¥5.34b market cap, or US$36.9m). Tillkännagivande • Apr 23
WOLVES HAND Co., Ltd. to Report Q3, 2025 Results on May 15, 2025 WOLVES HAND Co., Ltd. announced that they will report Q3, 2025 results on May 15, 2025 New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (98% net debt to equity). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (JP¥4.72b market cap, or US$33.0m). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥587, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 12x in the Healthcare industry in Japan. Tillkännagivande • Jan 24
WOLVES HAND Co., Ltd. to Report Q2, 2025 Results on Feb 14, 2025 WOLVES HAND Co., Ltd. announced that they will report Q2, 2025 results on Feb 14, 2025 Tillkännagivande • Jan 08
WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda. WOLVES HAND Co., Ltd. (TSE:194A) acquired Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. A cash consideration will be paid by WOLVES HAND Co., Ltd. As part of consideration, an undisclosed value is paid towards assets of Animal hospital business at Yasuda Animal Hospital. The expected completion of the transaction is January 6, 2025.
WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to JP¥980, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 16x in the Healthcare industry in Japan. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to JP¥1,125, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Reported Earnings • Aug 14
Full year 2024 earnings released: EPS: JP¥75.15 (vs JP¥68.16 in FY 2023) Full year 2024 results: EPS: JP¥75.15 (up from JP¥68.16 in FY 2023). Revenue: JP¥4.99b (up 7.3% from FY 2023). Net income: JP¥558.0m (up 10% from FY 2023). Profit margin: 11% (in line with FY 2023). Tillkännagivande • Aug 09
WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. on August 8, 2024. For the period ending August 31, 2023, Soyokaze Co., Ltd. reported total revenue of ¥290 million, EBIT of ¥29 million and net income of ¥22 million. As of August 31, 2023, Soyokaze Co., Ltd. reported total assets of ¥191 million and total common equity of ¥99 million. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to JP¥783, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 15x in the Healthcare industry in Japan. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to JP¥1,149, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Healthcare industry in Japan. Board Change • Jun 30
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Outside Director Hiroshi Nakata was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jun 21
WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million. WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 686,400
Price\Range: ¥770
Discount Per Security: ¥61.6
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 176,700
Price\Range: ¥770
Discount Per Security: ¥61.6
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 50,000
Price\Range: ¥770
Discount Per Security: ¥61.6
Transaction Features: Sponsor Backed Offering